Hood River Capital Management LLC Ligand Pharmaceuticals Inc Transaction History

Hood River Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$105.93 - $142.47 $23.3 Million - $31.3 Million	-219,803 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$128.36 - $272.13 $474,803 - $1.01 Million	3,699 Added 1.71%	219,803 $29.8 Million
Q3 2018 Nov 14, 2018	BUY	$211.18 - $274.49 $1.05 Million - $1.36 Million	4,952 Added 2.35%	216,104 $59.3 Million
Q2 2018 Jul 30, 2018	BUY	$150.77 - $207.98 $4.49 Million - $6.19 Million	29,774 Added 16.42%	211,152 $43.7 Million
Q1 2018 May 07, 2018	BUY	$138.63 - $182.62 $462,885 - $609,768	3,339 Added 1.88%	181,378 $30 Million
Q4 2017 Feb 07, 2018	BUY	$128.36 - $147.04 $1.66 Million - $1.9 Million	12,937 Added 7.84%	178,039 $24.4 Million
Q3 2017 Nov 07, 2017	BUY	$120.91 - $137.94 $20 Million - $22.8 Million	165,102	165,102 $22.5 Million

276

18.5M

30.8K

5.2K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.89B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Hood River Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Hood River Capital Management LLC with notifications on news.